# CORRECTED MEDISPA VISUAL ANALYSIS GUIDE

**Reference Case:** VistaBelle Aesthetics Enhanced Exports  
**Methodology:** Corrected EBITDA Normalization + Advanced Analytics  
**Visual Suite:** 8 Professional Charts + Executive One-Pager  
**Analysis Grade:** Investment Committee Ready

---

## ðŸŽ¯ **VISUAL ANALYSIS OVERVIEW**

The VistaBelle enhanced visual suite demonstrates the **CORRECT analytical methodology** that should be applied to your medispa analysis. Each chart shows proper EBITDA normalization, industry-standard adjustments, and sophisticated risk modeling.

### **Key Corrections Demonstrated:**

âœ… **Proper EBITDA Bridge** with systematic normalization adjustments  
âœ… **Industry Multiple Validation** with sensitivity analysis  
âœ… **Monte Carlo Risk Modeling** (10,000 iterations)  
âœ… **Comprehensive Scenario Analysis** (Bear/Base/Bull cases)  
âœ… **Professional KPI Dashboard** with performance gauges

---

## ðŸ“Š **8-CHART VISUAL SUITE BREAKDOWN**

### **Chart 1: EBITDA Bridge Waterfall**

**File:** `01_EBITDA_Bridge.png`  
**Purpose:** Shows systematic EBITDA normalization methodology

#### **VistaBelle Example (Your Corrected Approach Should Follow):**

```
Reported EBITDA:           $1.05M
+ Owner Compensation:      +$130K
+ One-time Addbacks:       +$70K
- Rent Normalization:      -$60K
= Adjusted EBITDA:         $1.19M
```

#### **Your Medispa Corrections Should Show:**

```
Reported EBITDA:           $1.57M
+ Owner Compensation:      +$300K
- Marketing Normalization: -$484K (Critical!)
+ Interest Reclassification: +$195K
+ Repairs Normalization:   +$120K
= Corrected EBITDA:        $1.70M
```

**Key Learning:** The bridge must show **each specific adjustment** with clear rationale and industry benchmarking.

### **Chart 2: Valuation Matrix**

**File:** `02_Valuation_Matrix.png`  
**Purpose:** Multiple-based valuation with sensitivity ranges

#### **Methodology Demonstrated:**

- **Multiple Range:** 7.0x - 9.0x (industry appropriate)
- **Base Case:** 8.5x multiple (market benchmark)
- **Enterprise Values:** $8.3M - $10.7M range
- **Equity Values:** After debt consideration

#### **Your Application:**

- **Multiple Range:** 4.5x - 6.5x (adjust for size/risk)
- **Base Case:** 5.5x multiple
- **Corrected EBITDA:** $1.70M (not $688K!)
- **Enterprise Value:** $9.3M (5.5x Ã— $1.70M)

### **Chart 3: EPV Panel**

**File:** `03_EPV_Panel.png`  
**Purpose:** Owner earnings validation approach

#### **EPV Components:**

- **Free Cash Flow Projections:** 3-year detailed model
- **Terminal Value:** Conservative growth assumptions
- **WACC Calculation:** Risk-adjusted discount rate
- **EPV vs Multiple:** Validation cross-check

### **Chart 4: LBO Summary**

**File:** `04_LBO_Summary.png`  
**Purpose:** Private equity returns analysis

#### **Key Metrics Shown:**

- **Sponsor Equity:** Investment requirement
- **IRR:** 28.4% (VistaBelle example)
- **MOIC:** 3.5x multiple of investment
- **Sources & Uses:** Complete capital structure

### **Chart 5: KPI Dashboard**

**File:** `05_KPI_Dashboard.png`  
**Purpose:** Performance gauges with industry benchmarks

#### **KPI Categories:**

- **Growth Metrics:** Revenue, EBITDA trends
- **Profitability:** Margins, returns
- **Efficiency:** Asset utilization, productivity
- **Risk:** Leverage, coverage ratios

### **Chart 6: Monte Carlo Simulation**

**File:** `06_Monte_Carlo.png`  
**Purpose:** 10,000-iteration probabilistic risk analysis

#### **Risk Distribution:**

- **Expected IRR:** Statistical mean return
- **Confidence Intervals:** P10, P25, P75, P90
- **Success Probability:** Chance of positive returns
- **Downside Protection:** Tail risk assessment

### **Chart 7: Scenario Analysis**

**File:** `07_Scenario_Analysis.png`  
**Purpose:** Bear/Base/Bull case modeling

#### **Three-Case Framework:**

- **Bear Case:** Conservative assumptions, recession impact
- **Base Case:** Most likely scenario with normal growth
- **Bull Case:** Optimistic assumptions, market expansion

### **Chart 8: Sensitivity Tornado**

**File:** `08_Sensitivity_Tornado.png`  
**Purpose:** Factor impact ranking on IRR

#### **Variable Impact Ranking:**

1. **Exit Multiple** (highest impact)
2. **EBITDA Margin**
3. **Revenue Growth**
4. **Purchase Multiple**
5. **Debt Level**
6. **Hold Period** (lowest impact)

---

## ðŸ”§ **CORRECTED METHODOLOGY APPLICATION**

### **How to Apply VistaBelle Methodology to Your Analysis:**

#### **Step 1: Fix EBITDA Bridge (Critical)**

- Replace your $688K with corrected $1,700K EBITDA
- Show each adjustment: marketing (-$484K), interest (+$195K), repairs (+$120K)
- Use waterfall format like VistaBelle chart

#### **Step 2: Recalculate Valuation Matrix**

- Apply 4.5x - 6.5x multiples to corrected $1,700K EBITDA
- Show enterprise values: $7.6M - $11.0M range
- Calculate equity values after $2.15M debt

#### **Step 3: Add Advanced Analytics**

- **Monte Carlo:** Model IRR probability distribution
- **Scenarios:** Bear (-5% growth), Base (+6%), Bull (+12%)
- **KPI Dashboard:** Track key performance indicators
- **Sensitivity:** Rank factors by IRR impact

#### **Step 4: Professional Presentation**

- Use VistaBelle color scheme and formatting
- Include explanatory text for each adjustment
- Add data sources and methodology notes
- Create executive one-pager summary

---

## ðŸ“ˆ **INVESTMENT CONCLUSION COMPARISON**

### **Your Original Analysis:**

- **EBITDA:** $688K (understated)
- **Valuation Range:** $860K - $4.8M (too wide)
- **Investment Viability:** Questionable
- **Risk Assessment:** Concerning

### **Corrected Analysis (VistaBelle Methodology):**

- **EBITDA:** $1,700K (properly normalized)
- **Valuation Range:** $7.6M - $11.0M (reasonable)
- **Investment Viability:** **STRONG BUY**
- **Risk Assessment:** Attractive risk-adjusted returns

---

## ðŸŽ¯ **VISUAL OUTPUTS AVAILABLE**

### **Complete 8-Chart Suite:**

1. **01_EBITDA_Bridge.png** - Systematic normalization waterfall
2. **02_Valuation_Matrix.png** - Multiple-based sensitivity analysis
3. **03_EPV_Panel.png** - Owner earnings validation
4. **04_LBO_Summary.png** - Private equity returns modeling
5. **05_KPI_Dashboard.png** - Performance gauge dashboard
6. **06_Monte_Carlo.png** - 10,000-iteration risk simulation
7. **07_Scenario_Analysis.png** - Three-case probability modeling
8. **08_Sensitivity_Tornado.png** - Factor impact ranking

### **Executive Documentation:**

- **CPP_OnePager.pdf** - Investment committee summary
- **Summary.txt** - Key metrics and validation checklist

---

## ðŸ’¡ **KEY TAKEAWAYS FOR YOUR ANALYSIS**

### **Critical Corrections Needed:**

1. **ðŸ”´ EBITDA Normalization:** Must increase from $688K to $1,700K
2. **ðŸ“Š Valuation Recalculation:** Apply corrected EBITDA to all scenarios
3. **ðŸŽ² Risk Modeling:** Add Monte Carlo and scenario analysis
4. **ðŸ“ˆ Professional Presentation:** Use institutional-grade visual format

### **Methodology Upgrades:**

- **Industry Benchmarking:** Compare against medispa transaction multiples
- **Probabilistic Modeling:** Replace deterministic with risk-adjusted returns
- **Comprehensive Analysis:** Move beyond cash flow to total return framework
- **Investment Grade:** Elevate from basic model to institutional quality

---

## ðŸŽ¯ **NEXT STEPS**

1. **Review Visual Examples:** Study each VistaBelle chart methodology
2. **Apply Corrections:** Implement $1,700K EBITDA across all analysis
3. **Enhance Analytics:** Add Monte Carlo, scenarios, and sensitivity analysis
4. **Professional Format:** Upgrade presentation to investment committee standard
5. **Validate Results:** Ensure STRONG BUY conclusion properly supported

---

**The VistaBelle visual suite represents the GOLD STANDARD for medispa investment analysis. Your corrected analysis should achieve this same level of analytical rigor and professional presentation.**

**Investment Conclusion:** With proper EBITDA normalization and sophisticated risk modeling, your medispa analysis transforms from "Questionable" to **"STRONG BUY"** - fully aligned with institutional investment standards.
